NASDAQ:BPMC
Blueprint Medicines Corporation Stock News
$106.55
+0.450 (+0.424%)
At Close: Jun 25, 2024
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 07'th Jul 2021
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
03:23pm, Thursday, 24'th Jun 2021
This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
12:47pm, Thursday, 17'th Jun 2021
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
03:50pm, Wednesday, 16'th Jun 2021
CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) f
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Jun 2021
CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board
Blueprint Medicines to Present at Upcoming Investor Conferences
08:00am, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical bene
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
08:00am, Monday, 17'th May 2021
CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 05'th May 2021
CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
05:29pm, Monday, 03'rd May 2021
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
10:31am, Friday, 30'th Apr 2021
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call Transcript
02:42pm, Thursday, 29'th Apr 2021
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call Transcript
Recap: Blueprint Medicines Q1 Earnings
08:01am, Thursday, 29'th Apr 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the
Blueprint Medicines Reports First Quarter 2021 Financial Results
07:00am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
08:00am, Thursday, 22'nd Apr 2021
CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.